Long-term safety of methylphenidate: sleep, growth, and adverse events in children with ADHD

Background and framing (~2 min) Methylphenidate remains the most widely used ADHD medication globally. As prescribing has expanded across age groups and treatment durations, real-world pharmacoepidemiological evidence now provides long-term safety data beyond the reach of clinical trials.

Why observational evidence? A brief methodological primer (~5 min) Randomised controlled trials form the evidence base for licensing, but are typically short in duration and powered for efficacy rather than long-term safety. Rare adverse events and developmental outcomes that have emerged over the years are largely invisible in trial settings. Observational approaches, including prospective cohorts such as ADDUCE and large-scale electronic healthcare database studies, fill this gap through extended follow-up and broader populations. Key methodological considerations, including confounding by indication and self-controlled designs, will be briefly discussed.

Sleep disturbances (~5 min) Methylphenidate can prolong sleep onset latency and reduce total sleep time. Current evidence, largely from smaller studies, suggests dose- and formulation-dependent effects; robust large-scale real-world data remain limited.

Growth: height, weight, and bone health (~10 min) Registry and cohort studies consistently show modest early height velocity reductions (~0.1–0.3 SD), BMI suppression of ~0.3–0.5 SD in the first year with adolescent rebound, and emerging bone mineral density deficits. Evidence from ADDUCE and population-based adult height data will be critically appraised.

Broader adverse event profile (~10 min) Further studies on cardiovascular outcomes (short-term reassurance versus cumulative dose-dependent signals), psychosis risk (methylphenidate versus amphetamine differences, dose-response relationships), and seizure risk across paediatric populations.

Closing remarks (~2 min)